0114 NewAmsterdam series A
BioCentury & Getty Images


Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

Jan 15, 2021 | 2:09 AM GMT

A broad syndicate has funded NewAmsterdam with a $196 million (€160 million) series A round to assess whether a well-traveled CETP inhibitor can find a place in the treatment paradigm for dyslipidemia.

Forbion, Morningside Ventures and Ascendant BioCapital led the round, which will fund a

Read the full 680 word article

How to gain access

Continue reading with a
two-week free trial.